CXCL8 in Tumor Biology and Its Implications for Clinical Translation

Xingyu Xiong; Xinyang Liao; Shi Qiu; Hang Xu; Shiyu Zhang; Sheng Wang; Jianzhong Ai; Lu Yang

doi:10.3389/fmolb.2022.723846

CXCL8 in Tumor Biology and Its Implications for Clinical Translation

Front Mol Biosci. 2022 Mar 15:9:723846. doi: 10.3389/fmolb.2022.723846. eCollection 2022.

Authors

Xingyu Xiong¹, Xinyang Liao¹, Shi Qiu^{1

2}, Hang Xu¹, Shiyu Zhang¹, Sheng Wang¹, Jianzhong Ai¹, Lu Yang¹

Affiliations

¹ Department of Urology, National Clinical Research Center for Geriatrics, Institute of Urology, West China Hospital of Sichuan University, Chengdu, China.
² Center of Biomedical Big Data, West China Hospital, Sichuan University, Chengdu, China.

Abstract

The chemokine CXCL8 has been found to play an important role in tumor progression in recent years. CXCL8 activates multiple intracellular signaling pathways by binding to its receptors (CXCR1/2), and plays dual pro-tumorigenic roles in the tumor microenvironment (TME) including directly promoting tumor survival and affecting components of TME to indirectly facilitate tumor progression, which include facilitating tumor cell proliferation and epithelial-to-mesenchymal transition (EMT), pro-angiogenesis, and inhibit anti-tumor immunity. More recently, clinical trials indicate that CXCL8 can act as an independently predictive biomarker in patients receiving immune checkpoint inhibitions (ICIs) therapy. Preclinical studies also suggest that combined CXCL8 blockade and ICIs therapy can enhance the anti-tumor efficacy, and several clinical trials are being conducted to evaluate this therapy modality.

Keywords: CXCL8; immunotherapy; tumor immune suppression; tumor microenvironment; tumor progression.

Publication types

Review